Roche is buying 89bio to get pegozafermin, a drug currently in two Phase 3 studies for the fatty liver disease MASH. Beyond the $2.4 billion payable when the deal closes, another $1.1 billion in contingent value right payments is tied to the achievement of commercial milestones for the projected blockbuster seller. The post Roche’s Metabolic…
Roche is buying 89bio to get pegozafermin, a drug currently in two Phase 3 studies for the fatty liver disease MASH. Beyond the $2.4 billion payable when the deal closes, another $1.1 billion in contingent value right payments is tied to the achievement of commercial milestones for the projected blockbuster seller. The post Roche’s Metabolic…
Roche is buying 89bio to get pegozafermin, a drug currently in two Phase 3 studies for the fatty liver disease MASH. Beyond the $2.4 billion payable when the deal closes, another $1.1 billion in contingent value right payments is tied to the achievement of commercial milestones for the projected blockbuster seller. The post Roche’s Metabolic…
Roberta Schwartz, Ph.D., the health system’s executive vice president and chief innovation officer, describes efficiencies gained from the new system
We’re in the middle of a fundamental shift that’s giving consumers more power and choice over their health coverage while creating healthy competition in the marketplace. Consumer expectations are justifiably rising, and people want a much more pleasant, frictionless and digital experience from their health plan – just like they get everyplace else in their…
[Sponsored] An upcoming webinar sponsored by Solera Health will explore how employers can develop benefit strategies that improve employee outcomes and fit their budgets. The post What Self-Insured Employers Should Look for in a Digital Health Vendor appeared first on MedCity News.
San Francisco – KFF announced today that Dr. Dave Ashok Chokshi, a practicing physician and health leader, has joined KFF’s Board of Trustees. Dr. Chokshi is a physician at Bellevue Hospital as well as Sternberg Family Professor of Leadership at the City College of New York.
Malingering, deliberately feigning or exaggerating symptoms appears to be rising. This shift brings with it a tangled web of clinical, operational, and ethical challenges that affect not only providers but also the patients most in need of timely, effective care. The post Behind “Rise of Malingering” in ER Psychiatry: Why Better Patient Classification Matters appeared…
Take part in our Reader Survey and help us continue to grow! The post Do You Value MedCity News? Take Our Survey! appeared first on MedCity News.
Biologist Grant Hokit came to this small meadow in the mountains outside Condon, Montana, to look for ticks. A hiking path crossed the expanse of long grasses and berry bushes. As Hokit walked the path, he carried a handmade tool made of plastic pipes taped together to hold a large rectangle of white flannel cloth….